http://sharetipsinfo.comJust get registered at Sharetipsinfo and earn positive returns
Arihant Capital has come out with its report on Supriya Lifescience. The research firm has recommended to ''Subscribe'' the ipo in its research report as on December 15, 2021.
Supriya Lifescience Ltd. is a major Indian manufacturer and supplier of active pharmaceutical ingredients with a niche product basket of 38 APIs across diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, antiasthmatic and anti-allergic. It is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45%-50% and 60%-65%, respectively, of the API exports from India, between FY17 and FY21
The company is amongst the largest exporters of Salbutamol Sulphate in India contributing to 31% of the API exports from India in FY21 in volume terms.
Valuation and Outlook
It also has additional land and backward integration plans which will augur well for the company in future. We have a positive view on the company and recommend investors to subscribe the IPO owing to attractive valuation.
Click Here:- Get 90% Stock Market tips With High Accuracy